a phase ii study of surufatinib combined with camrelizumab and mfolfox6 as second-line treatment for advanced prad

Conditions: Advanced Pancreatic Cancer

Summary: to preliminarily evaluate whether there is a survival benefit of surufatinib combined with camrelizumab and mfolfox6 as the second-line treatment for advanced pancreatic cancer, and to explore the feasibility of second-line and post-line treatment for advanced pancreatic cancer

second-line clinical study of surufatinib in combination with caralizumab advanced pancreatic cancer

Eligibility criteria:
inclusion criteria: 1. have full understanding of this study and voluntarily sign the informed consent form; 2. male and female aged between 18 and 75 years are eligible; 3. histologically or cytologically confirmed metastatic pancreatic cancer; 4. patients who have previously failed first-line gemcitabine-based chemotherapy or have disease progression/recurrence during previous neoadjuvant/adjuvant treatment or within 6 months after the end of treatment are considered to have failed first-line systemic chemotherapy; neoadjuvant/adjuvant treatment plan also gemcitabine-based chemotherapy; 5. presence of at least one measurable target lesion for further evaluation according to recist criteria; 6. eastern cooperative oncology group (ecog) performance status 0-1; 7. predicted survival ≥12 weeks; 8. males or female of childbearing potential must: agree to use using a reliable form of contraception (eg, oral contraceptives, intrauterine device, control sex desire, double barrier method of condom and spermicidal) during the treatment period and for at least 6 months after the last dose of study drug. exclusion criteria: 1. participated in other anti-tumor drug clinical trials within 28 days; 2. have previously received any anti-pd-1 antibody, anti-pd-l1 antibody, anti-pd-l2 antibody or anti-cytotoxic t lymphocyte-associated antigen-4 (ctla-4) antibody or acted on t cell costimulation or checkpoints treatment with any other antibodies of the pathway (such as ox40, cd137, etc.); 3. have previously received anti-vascular endothelial growth factor/vascular endothelial growth factor receptor (vegf/vegfr) targeted drug treatment; 4. those who are known to be allergic to any of the drugs in the study; 5. brain metastasis accompanied by symptoms or symptom control time \<2 months; 6. the subject has suffered from other malignant tumors in the past or at the same time within 5 years (except cured basal cell carcinoma of the skin and cervical cancer in situ); 7. insufficient bone marrow hematopoietic function (without blood transfusion within 14 days): 1. absolute neutrophil count (anc) \<1.5×109/l; 2. platelets \<100×109/l; 3. hemoglobin \<8g/dl. 8. liver abnormalities: 1. when there is no liver metastasis, alt, ast or alp\>2.5×the upper limit of the normal reference range (uln); when there is liver metastasis, alt, ast or alp\>5×uln; 2. serum total bilirubin \>1.5×uln (gilber syndrome \>3×uln); 3. decompensated cirrhosis (child-pugh liver function grade b or c); 4. hepatitis b surface antigen (hbsag) positive and hepatitis b virus dna copy number ≥2000iu/ml (those who are hbsag positive and hepatitis b virus dna copy number \<2000iu/ml need to receive at least 2 weeks of anti-hbv treatment before taking the first dose) ; 5. hepatitis c virus (hcv) antibody positive and hcvrna test positive. 9. kidney abnormalities: 1. serum creatinine\>1.5×uln; 2. routine urine test shows urine protein ≥++, and the 24-hour urine protein quantification is confirmed to be \>1.0g; 3. renal failure requiring hemodialysis or peritoneal dialysis; 4. past history of nephrotic syndrome.；